Skin Disease-Focused AnaptysBio Earns Analyst Upgrade On Positive Outlook For Clinical Triggers
Skin Disease-Focused AnaptysBio Earns Analyst Upgrade On Positive Outlook For Clinical Triggers
Monday, AnaptysBio Inc (NASDAQ:ANAB) reported a fourth-quarter 2023 EPS of $(1.59), slightly better than the consensus of $(1.60).
周一，AnaptysBio Inc（纳斯达克股票代码：ANAB）公布的2023年第四季度每股收益为1.59美元（1.59美元），略好于市场普遍预期的美元（1.60美元）。
The company reported sales of $9.01 million, surpassing the consensus of $2.23 million.
该公司公布的销售额为901万美元，超过了市场预期的223万美元。
The company's year-end 2023 cash and investments of $417 million are expected to provide a cash runway through year-end 2026.
该公司2023年年底的4.17亿美元现金和投资预计将在2026年底之前提供现金流。
Wedbush upgraded AnaptysBio, anticipating that a sequence of derivative developments and the company's internal clinical triggers will boost the company's stock in the next 1-1.5 years.
Wedbush对AnaptysBio进行了升级，预计一系列衍生品开发和公司的内部临床触发因素将在未来1-1.5年内提振该公司的股票。
Wedbush upgrades AnaptysBio from Neutral to Outperform, with a price target of $34, up from $20.
Wedbush将AnaptysBio从中性上调至跑赢大盘，目标股价从20美元上调34美元。
The company maintained guidance for Phase 2 data for its ANB032 in atopic dermatitis patients and Phase 2b data for rosnilimab in rheumatoid arthritis in mid-2025, and Phase 2 results in ulcerative colitis in the first half of 2026.
该公司维持了2025年中期特应性皮炎患者的 ANB032 的2期数据和类风湿关节炎中rosnilimab的2b期数据的指导方针，以及2026年上半年溃疡性结肠炎的2期结果的指导方针。
Before AnaptysBio announces its results, Wedbush anticipates a significant development from its main competitor in the PD-1 agonist field, Eli Lilly And Co (NYSE:LLY). Eli Lilly's peresolimab showed enhancements in ACR20 response rates and DAS28-CRP scores compared to placebo at the highest doses.
在AnaptysBio公布业绩之前，Wedbush预计其在PD-1激动剂领域的主要竞争对手礼来公司（纽约证券交易所代码：LLY）将取得重大进展。与最高剂量的安慰剂相比，礼来公司的peresolimab显示，ACR20 的反应率和 DAS28-CRP 分数都有所提高。
However, there were no notable enhancements in ACR50 or ACR70 response rates, suggesting a restricted depth of response for patients individually and a potential opportunity for improvement with rosnilimab.
但是，ACR50 或 ACR70 的反应率没有显著提高，这表明患者的个体反应深度有限，而使用 rosnilimab 可能有改善的机会。
According to a Wedbush analyst, rosnilimab shows promising potential for top-tier effectiveness due to its targeted epitope.
根据Wedbush的一位分析师的说法，由于其靶向表位，rosnilimab显示出具有一流疗效的巨大潜力。
By attaching to a specific area near the cell membrane on PD-1, rosnilimab doesn't block other signaling molecules from interacting between T cells and antigen-presenting cells. This permits the creation of a strong immune connection and ensures efficient delivery of inhibitory signals.
通过附着在PD-1细胞膜附近的特定区域，rosnilimab不会阻断其他信号分子在T细胞和抗原呈递细胞之间相互作用。这允许建立强大的免疫连接，并确保抑制信号的有效传递。
Price Action: ANAB shares are up 10.70% at $25.86 on the last check Tuesday.
价格走势：周二的最后一次支票中，ANAB股价上涨10.70％，至25.86美元。
Photo by louis-reed for Unsplash
louis-reed 为 Unsplash 拍摄的照片